Gamida Cell Stocks 2024

Gamida Cell Stocks

110.05 M

Gamida Cell Dividend yield

Ticker

GMDA

ISIN

IL0011552663

WKN

A2N7XM

In 2024, Gamida Cell had 110.05 M outstanding stocks, a 0% change from the 110.05 M stocks in the previous year.

The Gamida Cell Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2030e110.05
2029e110.05
2028e110.05
2027e110.05
2026e110.05
2025e110.05
2024e110.05
2023110.05
202263.83
202159.25
202043.73
201933.67
201824.93
201724.3
201624.3

Gamida Cell Aktienanalyse

What does Gamida Cell do?

The company Gamida Cell Ltd was founded in 1998 in Jerusalem, Israel and is involved in the development and manufacture of cell therapy products for various diseases. The company has had an exciting history since its inception, including a number of successes and milestones. Gamida Cell's business model is based on the production of cell therapy products for patients suffering from severe diseases. These include blood diseases such as leukemia, lymphoma, or sickle cell anemia. The company uses a unique technology platform called "NiCord," which allows for the extraction and expansion of cells from umbilical cord blood to provide a larger number of cells for transplantation. This platform offers a way to overcome some of the limitations and challenges associated with the use of bone marrow or stem cell donors. Gamida Cell has made significant progress in the development of cell therapy products in recent years. The company is currently working on the development of therapies for various indications such as blood diseases, solid tumors, and autoimmune diseases. Another goal of Gamida Cell is to use its technology platform for the development of drugs for other indications. The company has various divisions in which it operates. The primary division is research and development of cell therapies. However, the company also has a manufacturing facility for the production of its products and a clinical studies department responsible for conducting studies and tests of therapeutics. Gamida Cell collaborates closely with research institutions and other companies in the biotechnology industry to further develop its technology platform and advance the progress of cell therapies overall. Gamida Cell currently offers a range of products, starting with its flagship product "NiCord." NiCord is a cell therapy made from umbilical cord blood cells and can be used for transplantation in patients with blood diseases such as leukemia or lymphoma. The company is also working on the development of additional products, including a cell therapy for solid tumors and a treatment for autoimmune diseases. In recent years, Gamida Cell has received several awards and recognitions. The company has attracted several leading scientists and researchers who collaborate closely with Gamida Cell to further develop the company's technology platform and create new therapies. At the same time, Gamida Cell has also carried out several capital increases to advance research and product development. Overall, Gamida Cell has an excellent reputation in the biotech industry. The company has shown that it can play a leading role in the development of cell therapies that can improve the lives of patients with severe diseases. With the growing demand for new treatment options and the rapid progress in the field of biotech, Gamida Cell is well positioned to continue expanding and developing new therapies that have the potential to change the lives of millions of people worldwide. Gamida Cell ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Gamida Cell's Shares Outstanding

Gamida Cell's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Gamida Cell’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Gamida Cell’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Gamida Cell’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Gamida Cell Stock

How many stocks are there of Gamida Cell?

The current number of stocks of Gamida Cell is 110.05 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Gamida Cell are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Gamida Cell evolved in recent years?

The number of shares of Gamida Cell has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Gamida Cell as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Gamida Cell?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Gamida Cell pay?

Over the past 12 months, Gamida Cell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Gamida Cell is expected to pay a dividend of 0 USD.

What is the dividend yield of Gamida Cell?

The current dividend yield of Gamida Cell is .

When does Gamida Cell pay dividends?

Gamida Cell pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Gamida Cell?

Gamida Cell paid dividends every year for the past 0 years.

What is the dividend of Gamida Cell?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Gamida Cell located?

Gamida Cell is assigned to the 'Health' sector.

Wann musste ich die Aktien von Gamida Cell kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Gamida Cell from 4/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/16/2024.

When did Gamida Cell pay the last dividend?

The last dividend was paid out on 4/16/2024.

What was the dividend of Gamida Cell in the year 2023?

In the year 2023, Gamida Cell distributed 0 USD as dividends.

In which currency does Gamida Cell pay out the dividend?

The dividends of Gamida Cell are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Gamida Cell

Our stock analysis for Gamida Cell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gamida Cell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.